You are here

  • Home
  • Archive
  • Volume 99, Issue 5
  • Comparison of ketorolac 0.4% and nepafenac 0.1% for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo-controlled randomised study

Responses

Article menu

Download PDFPDF

Clinical science
Comparison of ketorolac 0.4% and nepafenac 0.1% for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo-controlled randomised study
Free
Compose a Response to This Article
Compose Response

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on: 22 March 2016
    Topical non-steroidal anti-inflammatory drugs to prevent cystoid macular oedema after cataract extraction: Are they effective?
    • Andres B. Alberto, Resident in Ophthalmology
    • Other Contributors:
      • The Journal Club Group: Candelaria Pinto Herrera, Jacqueline Agustino Rodriguez, Denisse Angel Pereira, Alicia Pareja Rios, Eliseo Quijada Fumero, Luis Cordoves Dorta, Elena de Armas Ramos, Alejandro Jimenez Sosa, Valentin T. Diaz Aleman.

    We have read with interest the paper by Tzelikis et al. entitled: "Comparison of ketorolac 0.4% and nepafenac 0.1% for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo- controlled randomised study" [Br J Ophthalmol 2015;99(5):654-658].

    In order to consider as statistically similar the effects of ketorolac 0.4%, 0.1% nepafenac and placebo, the authors really needed to have...

    Show More
    Conflict of Interest:
    None declared.
  • Published on: 22 March 2016
    Ketorolac does prevent retinal thickening and CME in routine cataract surgery

    Your study actually confirms the data that we reported in the lead article of the AJO in October 2008 showing the benefit of ketorolac in preventing CME and retinal thickening after routine cataract surgery. To demonstrate statistical significance for CME, it requires a sample size of close to 400 patients per group. Your data clearly shows a trend to decreased retinal thickening when a NSAID is used in conjunction with...

    Show More
    Conflict of Interest:
    None declared.